What Are Wall Street Analysts' Target Price for Healthpeak Properties Stock?

Core Viewpoint - Healthpeak Properties, Inc. is a healthcare-focused real estate investment trust (REIT) that has experienced mixed performance in the market, with a significant decline over the past year but a positive year-to-date performance. Performance Summary - Over the past 52 weeks, Healthpeak's shares have declined by 18.1%, while the S&P 500 Index has gained 15.5% [2] - Year-to-date, Healthpeak's stock is up 5.2%, outperforming the S&P 500's increase of 1.9% [2] - Compared to the State Street Real Estate Select Sector SPDR Fund, Healthpeak has also underperformed over the past year but has exceeded its performance year-to-date [3] Recent Developments - On January 7, Healthpeak announced plans for an IPO of Janus Living, a dedicated REIT for senior housing, contributing a portfolio of 34 communities and 10,422 units while retaining a majority stake [4] - The IPO is targeted for the first half of 2026, pending market and regulatory conditions [4] Financial Outlook - For FY2025, analysts project Healthpeak's funds from operations (FFO) to grow by 1.1% year-over-year to $1.83 per share [5] - The company has a strong earnings surprise history, meeting or exceeding consensus estimates in the last four quarters [5] Analyst Ratings - Among 20 analysts covering Healthpeak, the consensus rating is a "Moderate Buy," with eight "Strong Buy," two "Moderate Buy," and ten "Hold" ratings [5] - Goldman Sachs initiated coverage with a "Neutral" rating and a price target of $17, noting the company's portfolio transformation since 2019 [6] - The mean price target of $19.83 indicates a 17.2% premium from current levels, while the highest target of $29 suggests a potential upside of 71.4% [7]